• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

    11/14/24 4:31:50 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email
    SC 13D/A 1 d875555dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Nautilus Biotechnology, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    63909J 108

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 14, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 63909J 108

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Advisors LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,594,211

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,594,211

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,594,211

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     10.0%

    14.  

     Type of Reporting Person (See Instructions)

     

     IA


    CUSIP No. 63909J 108

     

     1.    

     Names of Reporting Persons.

     

     Joseph Edelman

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,594,211

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,594,211

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,594,211

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     10.0%

    14.  

     Type of Reporting Person (See Instructions)

     

     IN


    CUSIP No. 63909J 108

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Life Sciences Master Fund, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     12,428,351

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     12,428,351

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     12,428,351

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     9.9%

    14.  

     Type of Reporting Person (See Instructions)

     

     CO


    Item 1.

    Security and Issuer

    Item 1 of the Schedule 13D is amended and restated as follows:

    This Schedule 13D relates to the shares of common stock, $0.0001 par value per share (“Common Stock”), of Nautilus Biotechnology, Inc., a Delaware corporation (the “Issuer”), which has its principal executive offices at 2701 Eastlake Avenue, East Seattle, Washington 98102.

     

    Item 2.

    Identity and Background

    Item 2 of the Schedule 13D is amended and restated as follows:

     

    (a)

    This Amendment No. 2 to the Schedule 13D is being filed by Perceptive Advisors LLC (“Perceptive Advisors”), Joseph Edelman (“Mr. Edelman”) and Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund,” and together with Perceptive Advisors and Mr. Edelman, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”). Perceptive Advisors serves as the investment advisor to the Master Fund and Mr. Edelman is the managing member of Perceptive Advisors. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached as Exhibit 1 to the initial Schedule 13D filed June 21, 2021.

     

    (b)

    The address of the principal business office of each of the Reporting Persons is 51 Astor Place 10th Floor, New York, NY 10003.

     

    (c)

    The principal business of Perceptive Advisors is managing funds in connection with purchasing, holding and selling securities for investment purposes. The principal business of the Master Fund is to invest in securities. The principal occupation of Mr. Edelman is as the managing member of Perceptive Advisors and other related entities.

     

    (d)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Amendment No. 2 to Schedule 13D, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)

    During the last five years, none of the Reporting Persons, nor to the Reporting Persons’ knowledge, any of the persons listed on Schedule A to this Amendment No. 2 to Schedule 13D, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws, other than the previously announced settlement order entered into by Perceptive Advisors with the Securities and Exchange Commission dated September 6, 2022 (File No. 3-21031).

     

    (f)

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.

    Schedule A to this Amendment No. 2 to Schedule 13D sets forth information regarding the Master Fund.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is amended and supplemented as follows:

     

    (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 125,563,965 outstanding shares of Common Stock as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2024.

     

    (b)

    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

    By:

     

    Perceptive Advisors LLC

    By:

     

    /s/ Joseph Edelman

     

    Name: Joseph Edelman

     

    Title: Managing Member


    Schedule A

    The following sets forth the name, address, principal occupation, citizenship and beneficial ownership of Common Stock of each director of the Master Fund.

     

    Master Fund

    Name and Citizenship

      

    Position

      

    Principal Business Address

      

    Beneficial Ownership of

    Ordinary Shares

    Scott Dakers

    (United Kingdom)

       Director   

    c/o Elian Fiduciary Services (Cayman) Limited

    190 Elgin Avenue, George Town

    Grand Cayman KY1-9007

    Cayman Islands

       None

    Ernest A. Morrison

    (United Kingdom)

       Director   

    Cox Hallett Wilkinson

    Milner House

    18 Parliament Street

    P.O. Box HM 1561

    Hamilton HM FX

    Bermuda

       None

    James Nicholas

    (United States)

       Director   

    c/o GenesisPoint LLC

    30 Old Kings Highway S

    Darien, CT 06820

       None
    Get the next $NAUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings